Evidence map›Paper›PMID 35013169›Full record

ArticleNature communications2022

A mass spectrometric method for in-depth profiling of phosphoinositide regioisomers and their disease-associated regulation.

Shin Morioka, Hiroki Nakanishi, Toshiyoshi Yamamoto, Junya Hasegawa, Emi Tokuda, Tomoya Hikita, Tomoko Sakihara, Yuuki Kugii, Chitose Oneyama, Masakazu Yamazaki and 3 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
5.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. A PI(3,5)PNature communications · 2026
    Article
  5. Oncometabolite 5-IPNature chemical biology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. The expanding organelle lipidomes: current knowledge and challenges.Cellular and molecular life sciences : CMLS · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Shin Morioka *Department of Biochemical Pathophysiology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, 113-8510, Japan.
Hiroki Nakanishi *Research Center for Biosignal, Akita University, Akita, 010-8543, Japan.
Toshiyoshi YamamotoDepartment of Biochemical Pathophysiology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, 113-8510, Japan.
Junya HasegawaDepartment of Biochemical Pathophysiology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, 113-8510, Japan.ORCID 0000-0003-1216-7468
Emi TokudaDepartment of Biochemical Pathophysiology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, 113-8510, Japan.ORCID 0000-0002-3837-4994
Tomoya HikitaDivision of Cancer Cell Regulation, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya, 464-8681, Japan.
Tomoko SakiharaDepartment of Biochemical Pathophysiology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, 113-8510, Japan.
Yuuki KugiiDepartment of Biochemical Pathophysiology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, 113-8510, Japan.
Chitose OneyamaDivision of Cancer Cell Regulation, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya, 464-8681, Japan.ORCID 0000-0002-5719-9431
Masakazu YamazakiDepartment of Cell Biology and Morphology, Akita University Graduate School of Medicine, Akita, 010-8543, Japan.ORCID 0000-0003-0050-0462
Akira SuzukiDivision of Molecular and Cellular Biology, Graduate School of Medicine, Kobe University, Kobe, 650-0017, Japan.
Junko SasakiDepartment of Biochemical Pathophysiology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, 113-8510, Japan. jsaspip@tmd.ac.jp.
Takehiko SasakiDepartment of Biochemical Pathophysiology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, 113-8510, Japan. tsasaki.pip@mri.tmd.ac.jp.ORCID 0000-0003-1837-3748
Tokyo Medical and Dental University · JPAichi Cancer Center · JPAkita University · JPKobe University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phosphoinositides are a family of membrane lipids essential for many biological and pathological processes. Due to the existence of multiple phosphoinositide regioisomers and their low intracellular concentrations, profiling these lipids and linking a specific acyl variant to a change in biological state have been difficult. To enable the comprehensive analysis of phosphoinositide phosphorylation status and acyl chain identity, we develop PRMC-MS (Phosphoinositide Regioisomer Measurement by Chiral column chromatography and Mass Spectrometry). Using this method, we reveal a severe skewing in acyl chains in phosphoinositides in Pten-deficient prostate cancer tissues, extracellular mobilization of phosphoinositides upon expression of oncogenic PIK3CA, and a unique profile for exosomal phosphoinositides. Thus, our approach allows characterizing the dynamics of phosphoinositide acyl variants in intracellular and extracellular milieus.

Indexed as

MetabolomeAnimalsChromatography, AffinityClass I Phosphatidylinositol 3-KinasesEpidermal Growth FactorExosomesGene ExpressionHEK293 CellsHeLa CellsHumansMaleMass SpectrometryMicePC-3 CellsPhosphatidylinositolsProstateClass I Phosphatidylinositol 3-KinasescopanlisibEpidermal Growth FactorPhosphatidylinositolsPIK3CA protein, humanPTEN PhosphohydrolasePTEN protein, humanPyrimidinesQuinazolines

Identifiers

PMID35013169
PMCPMC8749000
OpenAlexW4205746286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.